Neuromuscular

The assistant professor of neurology at the University of Washington in St. Louis discussed a study she and colleagues conducted which revealed significant differences between practitioners in diagnosing cerebral palsy.

In addition to increased motor milestone achievement, the safety profile of risdiplam was consistent with that observed in previous studies, with no new safety signals identified.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending April 24, 2020.

Alnylam Pharmaceuticals recently completed enrollment in the phase 3 HELIOS-A clinical trial of the drug.

The chief medical advisor for the Muscular Dystrophy Association discussed the switch to virtual conferences and shared his insight on how the neuromuscular community can move forward amid COVID-19.